• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 10, 2015

View Archived Issues

In the clinic

Epizyme Inc., of Cambridge, Mass., said it dosed the first patient in a phase II trial of lead candidate tazemetostat (EPZ-6438) in patients with relapsed or refractory non-Hodgkin lymphoma. Read More

Regulatory front

The Biotechnology Industry Organization (BIO) issued a statements opposing an amendment to the 21st Century Cures Initiative legislation filed by Rep. Dave Brat (R-Va.) that would convert the mandatory funding for the NIH to discretionary funding. Read More

Other news to note

Porton Biopharma Ltd., of Salisbury, UK, was spun out of Public Health England's clinical drug development and production capability into a standalone, state-owned biopharmaceutical limited company that has been approved by the Secretary of State for Health. Read More

Stock movers

Read More

Financings

Clovis Oncology Inc., of Boulder, Colo., said it priced an underwritten public offering of 3.5 million shares of its common stock at $78 each for gross proceeds of $275 million. Read More

'Sirting' for better control in type 2 diabetes, Nusirt exploits metformin pathway

Nusirt Biopharma Inc. is a small biotech that has largely avoided the limelight, but ambitious goals to attack two major indications – type 2 diabetes and nonalcoholic steatohepatitis (NASH) – could quickly raise its profile. Read More

Globavir moves oncology program to Sorrento, which continues cancer march with Nantworks

Globavir Biosciences Inc. found a partner for its lead oncology program in Sorrento Therapeutics Inc., which in turn inked another in a string of deals with the oncology syndicate Nantworks LLC that is being assembled by founder Patrick Soon-Shiong. Read More

New squamous NSCLC drug may be just around the corner

Marginal. Modest. Incremental. That's how the FDA and members of its Oncologic Drugs Advisory Committee (ODAC) described the 1.6-month improvement in overall survival (OS) Eli Lilly and Co.'s necitumumab demonstrated in a pivotal trial as a first-line treatment for squamous NSCLC. Read More

Mild market rebound, but China's public firms still suffering losses

HONG KONG – A dramatic plummeting in the value of publicly listed shares in Mainland China over the last month has wiped out roughly $3 trillion in wealth and raised fears of a collapse in the country's stock market, a collapse that could exacerbate slowing economic growth. Read More

Appointments and advancements

Hemoshear LLC, of Charlottesville, Va., named Vincent E. Aurentz president. He will continue with his business development responsibilities. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe